A SYNOPSIS ON ONYCHOMYCOSIS IN PATENT WITH HIGH DEGREE OF GLYCATED HEMOGLOBIN (HBA1C)

Essa Ajmi Alodeani, Mohammad Asrar Izhari, Mohammad Arshad*

ABSTRACT

Onychomycosis is an intercontinental disease burden and poses growing concern for the health-care establishment. It is a comparatively quotidian dermatologic manifestation. It is an infection of the nail plate or nail bed caused by fungus which leads to the imperceptible destruction of the nail plate, accounting for about half of all disordered nails and almost 30% of cutaneous mycoses. Variation in the incidence of the ailment reflects region and age. Usually it is not a self-limiting dermatologic representation and may trigger more infectious lesions at another site of the body owing to progressive nature of mycosis. Cosmetically unsightly affected nails may begin to be painful and lead to functional impairment. In case of patients with high degree of glycated hemoglobin (HbA1c) which is now days evaluated as an indicator of diabetes control, onychomycosis treatment becomes more imperative owing to the association between diabetes and the diabetic foot ulcer which one of the most serious sequelae of diabetes in the lower extremities. Especially lower limb sequelae are great contributors to hospitalization of diabetic patients accounting for the majority of in-hospital stay and huge consumption of resource leading to the great deal of economic setback of the health care system of the country. Approximately 15% of diabetic patients develop a lower extremity ulcer during the course of their ailment. Diabetic foot syndrome (DFS) affects 1 out of 5 diabetic patients at least once in his/her lifetime. The necessity of the selected treatment in these patients must be exercised to minimize or anticipate any adverse drug interactions as they concurrently use other medications. With the avalanche of scientific evidences and keeping all the aspects of the onycomycosis, it would be worth to undertake the subject under investigation.

Keywords: Onychomycosis, diabetic patients, glycated hemoglobin (HbA1c).